🟢 Tscan Therapeutics is trading 5% up today — immediate catalyst remains unclear

Tscan Therapeutics is trading 5.13% up at $0.32, with no clearly reported company-specific announcement on September 15, 2026.

• Latest notable developments were the September 2 strategic reorganization and September 8 executive retention program.
• The gain contrasts with broader biotech weakness, as XBI is down 2.11%.
• The stock remains in a low-price, volatile range; supplied data does not include volume.